Prophylaxis of chemotherapy‐induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non‐Hodgkin lymphoma (NADIR study). (23rd November 2018)

• Record Type: Journal Article
• Authors: Wolff, Thomas; Schulz, Holger; Losem, Christoph; Reichert, Dietmar; Hurtz, Hans‐Jürgen; Sandner, Reiner; Harde, Johanna; Grebhardt, Sina; Potthoff, Karin; Mueller, Udo; Fietz, Thomas
• Is Part Of: European journal of haematology. Volume 102:Number 2(2019)
• Page Start: 174
• Page End: 181
• Publication Date: 2018-11-23
• Subjects: chemotherapy‐induced febrile neutropenia -- granulocyte colony‐stimulating factor -- lipegfilgrastim -- non‐Hodgkin lymphoma -- primary prophylaxis -- routine clinical practice; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.13189
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Objective: The prospective non‐interventional study (NIS) NADIR was designed to evaluate both effectiveness and safety of prophylactic use of lipegfilgrastim (Lonquex ® ), a glycopegylated granulocyte colony‐stimulating factor, in cancer patients with different tumor entities undergoing chemotherapy in routine clinical practice. The primary objective was incidence of severe neutropenia, febrile neutropenia (FN), and neutropenia‐associated complications. Method: NADIR was a national, multicenter, prospective NIS. Results: Here, we present the data on patients with non‐Hodgkin lymphoma (NHL). Final analysis comprised 337 NHL patients having received ≥1 administration of lipegfilgrastim. Primary prophylaxis with lipegfilgrastim was documented in 78.7% of patients with high risk to develop FN. In total, ≥1 severe neutropenia (grade 3/4) was reported in 115 (34.1%) patients and ≥1 event of FN documented in 15 (4.5%) patients. Grade 3/4 infections were reported in 22 (6.5%) patients overall. Most frequently reported adverse events (AEs) related to lipegfilgrastim in total were bone pain (5.4%), leukocytosis (2.1%), back pain (1.8%), platelet count decreased (1.2%), and myalgia (1.2%). Fatal serious AEs were documented in 9 (2.7%) patients; none were attributable to lipegfilgrastim. Conclusion: Prophylaxis or therapeutic intention with lipegfilgrastim in NHL patients in routine clinical practice showed similar effectiveness and safety as demonstrated in the pivotal trials.